专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US6110717A Human RCE1 失效
公开(公告)号：US6110717A
公开(公告)日：2000-08-29
申请号：US22669
申请日：1998-02-12
申请人： Kristine Kay Kikly , Anne M Knab , Christopher Donald Southan
发明人： Kristine Kay Kikly , Anne M Knab , Christopher Donald Southan
IPC分类号： C12N9/64 , C12N9/10 , C07H21/04 , C12N1/20 , C12N15/00 , C12P21/06
CPC分类号： C12N9/6421
摘要： The hRCE1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hRCE1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

12. 发明授权

US06107473A Kringle-related clone HTHBZ47 失效
标题翻译： Kringle相关克隆HTHBZ47
公开(公告)号：US06107473A
公开(公告)日：2000-08-22
申请号：US39609
申请日：1998-03-16
申请人： Earl Francis Albone , Kristine Kay Kikly
发明人： Earl Francis Albone , Kristine Kay Kikly
IPC分类号： G01N33/50 , A61K31/00 , A61K31/7088 , A61K38/00 , A61K38/43 , A61K39/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P1/00 , A61P1/16 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/02 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/00 , A61P13/12 , A61P17/00 , A61P19/00 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/04 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07K14/47 , C07K14/705 , C07K16/18 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/58 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/566 , G01N33/577 , C07H21/04 , C07N15/12 , C07N15/58 , C07N15/63
CPC分类号： C07K14/47 , A61K39/00 , A61K48/00 , C07K2319/00
摘要： HTHBZ47 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HTHBZ47 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
摘要翻译：公开了通过重组技术产生这种多肽的HTHBZ47多肽和多核苷酸和方法。还公开了在治疗中使用HTHBZ47多肽和多核苷酸的方法，以及用于其的诊断测定法。

13. 发明授权

US5919660A Human requiem 失效
标题翻译：人类要求
公开(公告)号：US5919660A
公开(公告)日：1999-07-06
申请号：US881857
申请日：1997-06-24
申请人： Mitchell S Gross , Mark Robert Hurle , Kristine Kay Kikly
发明人： Mitchell S Gross , Mark Robert Hurle , Kristine Kay Kikly
IPC分类号： G01N33/50 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P1/16 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/14 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/00 , A61P43/00 , C07K14/47 , C07K14/715 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/00 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , C12R1/19 , C12R1/91 , G01N33/15 , G01N33/564 , G01N33/566 , G01N33/68 , G01N33/74 , C07H21/04 , C12N15/63
CPC分类号： C07K14/4747 , G01N33/564 , G01N33/6863 , G01N33/74 , A61K48/00 , C12N2799/026 , G01N2500/00 , G01N2510/00
摘要： Human REQUIEM polypeptides and DNA (RNA) encoding such REQUIEM and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such REQUIEM for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility. Antagonists against such REQUIEM and their use as a therapeutic to treat Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, CNS inflammation, osteoporosis, ischemia reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS, ALS, cererbellar degeneration, ischemic injury, myocardial infarction, AIDS, myelodysplastic syndromes, aplastic anemia, male pattern baldness, and head injury damage are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding REQUIEM polypeptide and for detecting altered levels of the polypeptide in a host.
摘要翻译：公开了人类REQUIEM多肽和编码这种REQUIEM的DNA（RNA）和通过重组技术产生此类多肽的方法。还公开了利用这种REQUIEM来治疗对病毒感染，肿瘤发生的易感性以及控制胚胎发生和组织稳态中的疾病和缺陷的方法，并且上述核酸序列可用于确定这种易感性的测定中。对抗这些REQUIEM的拮抗剂及其作为治疗性阿尔茨海默病，帕金森病，类风湿性关节炎，败血性休克，败血症，中风，CNS炎症，骨质疏松症，缺血再灌注损伤，与心血管疾病相关的细胞死亡，多囊肾病，凋亡还公开了心血管疾病，退行性肝病，MS，ALS，小脑变性，缺血性损伤，心肌梗塞，AIDS，骨髓增生异常综合征，再生障碍性贫血，男性型秃发和头部损伤损伤的内皮细胞。还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。还公开了用于检测编码REQUIEM多肽的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定法。

14. 发明授权

US08173124B2 Method to treat using antagonistic anti-hTNFSF13b human antibodies 有权
标题翻译：使用拮抗性抗hTNFSF13b人抗体治疗的方法
公开(公告)号：US08173124B2
公开(公告)日：2012-05-08
申请号：US12777306
申请日：2010-05-11
申请人： Kristine Kay Kikly
发明人： Kristine Kay Kikly
IPC分类号： A61K39/395
CPC分类号： C07K16/2875 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.
摘要翻译：公开了特异性结合TNFSF13b多肽的人单克隆抗体。这些抗体对hTNFSF13b具有高亲和力（例如，KD = 10-8M或更低），TNFSF13b解离的缓慢速率（例如，Koff = 10-3秒-1或更低）并且在体外和体内中和TNFSF13b活性。本发明的抗体在一个实施方案中可用于在患有hTNFSF13b活性有害的病症的人类受试者中抑制TNFSF13b活性。编码本发明抗体的核酸以及用于表达本发明抗体的载体和宿主细胞也包括在本发明中。

15. 发明授权

US07728109B2 Antagonistic anti-hTNFSF13b human antibodies 有权
标题翻译：拮抗性抗hTNFSF13b人抗体
公开(公告)号：US07728109B2
公开(公告)日：2010-06-01
申请号：US11952363
申请日：2007-12-07
申请人： Kristine Kay Kikly
发明人： Kristine Kay Kikly
IPC分类号： C07K16/24
CPC分类号： C07K16/2875 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.
摘要翻译：公开了特异性结合TNFSF13b多肽的人单克隆抗体。这些抗体对hTNFSF13b具有高亲和力（例如，KD = 10-8M或更低），TNFSF13b解离的缓慢速率（例如，Koff = 10-3秒-1或更低）并且在体外和体内中和TNFSF13b活性。本发明的抗体在一个实施方案中可用于在患有hTNFSF13b活性有害的病症的人类受试者中抑制TNFSF13b活性。编码本发明抗体的核酸以及用于表达本发明抗体的载体和宿主细胞也包括在本发明中。

16. 发明申请

US20090060920A1 DESACYL GHRELIN ANTIBODIES AND THERAPEUTIC USES THEREOF 审中-公开
标题翻译： DESACYL GHRELIN抗体及其治疗用途
公开(公告)号：US20090060920A1
公开(公告)日：2009-03-05
申请号：US11577530
申请日：2005-11-08
申请人： Derrick Ryan Witcher , Kristine Kay Kikly , Joseph Vincent Manetta
发明人： Derrick Ryan Witcher , Kristine Kay Kikly , Joseph Vincent Manetta
IPC分类号： A61K39/395 , C07K16/26 , A61P3/04 , A61P3/10
CPC分类号： C07K16/26 , A61K2039/505 , C07K2317/34 , C07K2317/55 , C07K2317/565
摘要： A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment or prevention of obesity and related disorders including, for example, Type II non-insulin dependent diabetes mellitus (NIDDM), Prader-Willi syndrome, eating disorders, hyperphagia, and impaired satiety. Additionally, such antibodies can be useful for the treatment or prevention of other disorders, including anxiety, gastric motility disorders (including e.g., irritable bowel syndrome and functional dyspepsia), insulin resistance syndrome, metabolic syndrome, dyslipidemia, atherosclerosis, hypertension, hyperandrogenism, polycystic ovarian syndrome, cancer, and cardiovascular disorders by administering a therapeutically effective amount of an anti-desacyl ghrelin monoclonal antibody of the invention.
摘要翻译：在Desacyl Ghrelin的氨基酸1-3中鉴定出中和表位。结合该表位的抗体属于本发明的范围，可以是鼠，嵌合或人源化抗体，抗体的免疫缀合物或其抗原结合片段。本发明的抗体可用于治疗或预防肥胖症和相关疾病，包括例如II型非胰岛素依赖性糖尿病（NIDDM），Prader-Willi综合征，进食障碍，食欲过盛和饱腹感受损。另外，这些抗体可用于治疗或预防其他疾病，包括焦虑，胃动力障碍（包括例如肠易激综合征和功能性消化不良），胰岛素抵抗综合征，代谢综合征，血脂异常，动脉粥样硬化，高血压，雄激素过多，多囊性卵巢综合征，癌症和心血管疾病，通过施用本发明的治疗有效量的抗脱酰基Ghrelin单克隆抗体。

17. 发明授权

US06417332B1 Human RCE1 失效
标题翻译：人类RCE1
公开(公告)号：US06417332B1
公开(公告)日：2002-07-09
申请号：US09603567
申请日：2000-06-26
申请人： Kristine Kay Kikly , Anne M Knab , Christopher Donald Southan
发明人： Kristine Kay Kikly , Anne M Knab , Christopher Donald Southan
IPC分类号： C07K100
CPC分类号： C12N9/6421
摘要： The hRCE1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hRCE1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
摘要翻译：公开了通过重组技术产生这种多肽的hRCE1多肽和多核苷酸和方法。还公开了在治疗中使用hRCE1多肽和多核苷酸的方法，以及用于其的诊断测定法。

18. 发明申请

US20120195904A1 METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES 审中-公开
标题翻译：使用抗人hTNFSF13B人抗体的方法
公开(公告)号：US20120195904A1
公开(公告)日：2012-08-02
申请号：US13444216
申请日：2012-04-11
申请人： Kristine Kay Kikly
发明人： Kristine Kay Kikly
IPC分类号： A61K39/395 , A61P19/02
CPC分类号： C07K16/2875 , A01K2217/05 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/53 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.
摘要翻译：公开了特异性结合TNFSF13b多肽的人单克隆抗体。这些抗体对hTNFSF13b具有高亲和力（例如，KD = 10-8M或更低），TNFSF13b解离的缓慢速率（例如Koff = 10-3秒-1或更低），并且在体外和体内中和TNFSF13b活性。本发明的抗体在一个实施方案中可用于在患有hTNFSF13b活性有害的病症的人类受试者中抑制TNFSF13b活性。编码本发明抗体的核酸以及用于表达本发明抗体的载体和宿主细胞也包括在本发明中。

19. 发明授权

US6090579A Human SDR2 cDNA clone 失效
标题翻译：人SDR2 cDNA克隆
公开(公告)号：US6090579A
公开(公告)日：2000-07-18
申请号：US991813
申请日：1997-12-16
申请人： Earl Francis Albone , Kristine Kay Kikly
发明人： Earl Francis Albone , Kristine Kay Kikly
IPC分类号： G01N33/50 , A61K31/00 , A61K31/70 , A61K31/7088 , A61K31/711 , A61K38/00 , A61K39/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P1/00 , A61P1/16 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/00 , A61P13/12 , A61P17/00 , A61P17/14 , A61P19/00 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/18 , A61P33/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/08 , A61P43/00 , C07K14/47 , C07K14/705 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/577 , G01N33/68 , C12N15/00
CPC分类号： C07K14/705 , G01N33/6893 , A61K38/00 , A61K39/00 , G01N2500/00
摘要： SDR2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing SDR2 polypeptides and polynucleotides in the design of protocols for the treatment of cancer, inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS inflamation, cerebellar degeneration, Alzheimer's disease, Parkinsons disease, multiple sclerosis, amylotrophic lateral sclerosis, head injury damage, and other neurological abnormalities, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemia reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other hematologic abnormalities, aplastic anemia, male pattern baldness, and bacterial, fungal, protozoan and viral infections, among others, and diagnostic assays for such conditions.
摘要翻译：公开了SDR2多肽和多核苷酸以及通过重组技术产生此类多肽的方法。还公开了在设计用于治疗癌症，炎症，自身免疫，过敏，哮喘，类风湿性关节炎，CNS炎症，小脑变性，阿尔茨海默氏病，帕金森病，多发性硬化，肌营养侧索硬化症的方案的设计中使用SDR2多肽和多核苷酸的方法，头部损伤损伤等神经系统异常，败血性休克，败血症，中风，骨质疏松症，骨关节炎，缺血再灌注损伤，心血管疾病，肾脏疾病，肝脏疾病，缺血性损伤，心肌梗死，低血压，高血压，艾滋病，骨髓增生异常综合征等血液学异常，再生障碍性贫血，男性型秃发，以及细菌，真菌，原生动物和病毒感染等，以及这些病症的诊断测定。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式